Human Papillomavirus Type 33 L1 Protein Vaccine: What Patients Should Know

What is the HPV Type 33 L1 Protein Vaccine?

The Human Papillomavirus (HPV) Type 33 L1 Protein vaccine is part of a 9-valent HPV vaccine called Gardasil 9. This vaccine contains proteins from nine different HPV types, including type 33, to protect against HPV infection and related diseases.1

Specifically, the vaccine contains the L1 protein from HPV type 33, which is produced using recombinant DNA technology in yeast cells. The L1 protein forms virus-like particles that mimic the HPV virus but do not contain genetic material, so they cannot cause infection.1

How Does It Work?

The vaccine works by stimulating the body's immune system to produce antibodies against the HPV L1 proteins. When a person is later exposed to the real virus, their immune system recognizes it and can quickly mount a response to prevent infection.1

The vaccine is adsorbed, meaning the proteins are attached to an aluminum-containing compound that helps boost the immune response.1

What Does It Treat and Prevent?

The HPV Type 33 L1 Protein vaccine, as part of Gardasil 9, helps prevent:

• Persistent anogenital HPV infection
• Cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
• Genital warts caused by HPV types 6 and 11
• Precancerous lesions like cervical intraepithelial neoplasia (CIN) and vulvar high-grade squamous intraepithelial lesions (vHSIL)23

How is It Administered?

The vaccine is given as an intramuscular injection, typically in the upper arm or thigh. The standard dosing schedule includes:

• 3 doses for individuals 15 years and older: at 0, 2, and 6 months
• 2 doses for children 9-14 years old: at 0 and 6-12 months apart14

Some ongoing studies are investigating extended dosing intervals and their impact on vaccine efficacy.4

Effectiveness

Clinical trials have shown that the 9-valent HPV vaccine, which includes the Type 33 L1 Protein, is highly effective in preventing HPV infections and related diseases. The vaccine stimulates a strong immune response, with high rates of seroconversion (development of antibodies) observed in study participants.4

Ongoing research is evaluating the vaccine's effectiveness in various populations, including immunocompromised individuals and adult males.56

Safety and Side Effects

The HPV Type 33 L1 Protein vaccine has been extensively tested and is considered safe. Common side effects may include:

• Pain, swelling, or redness at the injection site
• Headache
• Fever
• Nausea
• Dizziness1

Serious allergic reactions are rare but possible. Patients with a history of severe allergic reactions to vaccine components should not receive the vaccine.1

Who Should Get the Vaccine?

The HPV Type 33 L1 Protein vaccine, as part of Gardasil 9, is recommended for:

• Girls and boys aged 9-14 years (2-dose schedule)
• Adolescents and young adults aged 15-26 years who haven't been previously vaccinated (3-dose schedule)
• Some adults aged 27-45 years may benefit from vaccination after discussing with their healthcare provider14

The vaccine is not recommended for pregnant women or individuals with severe allergies to vaccine components.1

Ongoing Research

Several clinical trials are currently investigating the HPV Type 33 L1 Protein vaccine (as part of Gardasil 9) in various contexts:

• Extended dosing intervals in children and adolescents4
• Effectiveness in immunocompromised children and adolescents5
• Prevention of oral HPV infections in adult males6
• Use as adjuvant therapy in women treated for high-grade cervical lesions or early cervical cancer7
• Effectiveness in treating difficult-to-treat palmar or plantar warts8

These studies aim to expand our understanding of the vaccine's potential benefits and optimize its use in different populations.